These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 4539498)

  • 1. Primary thrombocythemia.
    Jamshidi K; Ansari A; Windschitl HE; Swaim WR
    Geriatrics; 1973 Jan; 28(1):121-33. PubMed ID: 4539498
    [No Abstract]   [Full Text] [Related]  

  • 2. [Essential thrombocythemia: conventional therapy].
    Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
    Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
    [No Abstract]   [Full Text] [Related]  

  • 3. Primary or hemorrhagic thrombocythemia.
    Silverstein MN
    Arch Intern Med; 1968 Jul; 122(1):18-22. PubMed ID: 5301705
    [No Abstract]   [Full Text] [Related]  

  • 4. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
    Randi ML; Fabris F; Girolami A
    Haematologica; 1999 Nov; 84(11):1049-50. PubMed ID: 10553169
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
    Passamonti F; Rumi E; Malabarba L; Arcaini L; Orlandi E; Brusamolino E; Pascutto C; Cazzola M; Lazzarino M
    Ann Hematol; 2004 Aug; 83(8):495-7. PubMed ID: 15175894
    [No Abstract]   [Full Text] [Related]  

  • 6. [Polycythemia vera].
    Nagy G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1970; 93(4):381-97. PubMed ID: 4195487
    [No Abstract]   [Full Text] [Related]  

  • 7. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of Polycythemia vera and thrombocythemia with myleran (busulphan).
    Epstein IS
    Isr J Med Sci; 1965 Jul; 1(4):797-9. PubMed ID: 5892718
    [No Abstract]   [Full Text] [Related]  

  • 10. Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a polycythemia Vera Study Group report.
    Murphy S; Rosenthal DS; Weinfeld A; Briere J; Faguet GB; Knospe WH; Landaw SA; Laszlo J; Pisciotta AV; Tartaglia AP
    Cancer Treat Rep; 1982 Jul; 66(7):1495-500. PubMed ID: 7046930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients.
    Brusamolino E; Canevari A; Salvaneschi L; Merante S; Bernasconi C
    Cancer Treat Rep; 1984 Nov; 68(11):1339-42. PubMed ID: 6541969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
    Sironi M; Bertola G; Lodato A; Spinelli M; Sciariada L
    Acta Haematol; 2003; 109(3):161-2. PubMed ID: 12714827
    [No Abstract]   [Full Text] [Related]  

  • 13. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
    Randi ML; Fabris F; Ruzzon E; Pacquola E; Cella G; Girolami A
    Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients.
    Chistolini A; Mazzucconi MG; Ferrari A; la Verde G; Ferrazza G; Dragoni F; Vitale A; Arcieri R; Mandelli F
    Haematologica; 1990; 75(6):537-40. PubMed ID: 2098295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Postextraction hemorrhage as 1st manifestation of polycythemia vera (Vaquez-Osler disease)].
    Veverka K; Kase F; Císar F
    Cesk Stomatol; 1967 Mar; 67(2):110-3. PubMed ID: 5297858
    [No Abstract]   [Full Text] [Related]  

  • 16. [Primary hemorrhagic thrombocythemia. 3 cases].
    Torre-Lopez E; Sanchez-Medal L
    Sangre (Barc); 1971; 16(3):305-13. PubMed ID: 5287077
    [No Abstract]   [Full Text] [Related]  

  • 17. [Present treatment of the Vaquez's disease].
    Vallée G; Boivin P; Dormont J; Soulier JP
    Presse Med (1893); 1969 Mar; 77(14):517-9. PubMed ID: 5783371
    [No Abstract]   [Full Text] [Related]  

  • 18. Studies on the phagocytic activity of neutrophilic leukocytes.
    Brandt L
    Scand J Haematol Suppl; 1967; 2():1-126. PubMed ID: 5243720
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
    Passamonti F; Lazzarino M
    Leuk Lymphoma; 2003 Sep; 44(9):1483-8. PubMed ID: 14565648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombocythemia and coronary artery disease.
    Scheffer MG; Michiels JJ; Simoons ML; Roelandt JR
    Am Heart J; 1991 Aug; 122(2):573-6. PubMed ID: 1858644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.